Research on psoriasis pathogenesis has largely increased knowledge on skin biology in
general. In the past 15 years, breakthroughs in the understanding of the pathogenesis of …

Interleukin-17 (IL-17) is an essential proinflammatory cytokine, which is mainly secreted by
the CD4+ helper T cells (Th17 cells) and subsets of innate lymphoid cells. IL-17A is …

Background Risankizumab, an interleukin (IL)-23 p19 inhibitor, was evaluated for safety and
efficacy as induction therapy in patients with moderately to severely active Crohn's disease …

Background The efficacy and safety of risankizumab as compared with ustekinumab in
patients with Crohn's disease are unknown. Methods In this phase 3b, multicenter, open …

Importance Recent studies have shown an association between psoriasis and nonalcoholic
fatty liver disease (NAFLD) in US inpatients, but the association is still unclear in the …

Summary Background The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in
psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL …

Psoriasis is a chronic, immune-mediated, inflammatory disease that is pathogenically driven
by proinflammatory cytokines. This article reviews the immunologic role of interleukin (IL)-17 …

Background Risankizumab is a humanised IgG1 monoclonal antibody that binds to the p19
subunit of interleukin-23, inhibiting this key cytokine and its role in psoriatic inflammation …

Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US
population. This guideline addresses important clinical questions that arise in psoriasis …

Objective To update the European League Against Rheumatism (EULAR) recommendations
for the pharmacological treatment of psoriatic arthritis (PsA). Methods According to the …